Toboroz
A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
NCT07418034· 2. fázis· University of Maryland, Baltimore· Forrás
Contact: Kelly Kitzmiller
Toboroz
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
NCT07745361· 2. fázis· Monte Rosa Therapeutics, Inc· Forrás
Contact: Monte Rosa Therapeutics Sponsor
Toboroz
Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer
NCT07147231· 1/2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Daniel Shu (principal investigator)
Még nem toboroz
GCC 2545- Improving Post-Radiotherapy Respiratory Function Through Sparing Serial and Parallel Components in the Lung
NCT07679607· 2. fázis· University of Maryland, Baltimore· Forrás
Contact: Caitlin Eggleston, MPH
Toboroz
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
NCT07452458· 3. fázis· NRG Oncology· Forrás
Contact: Mark V. Mishra (principal investigator)
Toboroz
GCC 2546- Motion Management
NCT07398209· University of Maryland, Baltimore· Forrás
Contact: Caitlin Eggleston, MPH
Toboroz
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
NCT07200830· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Zaker H. Rana (principal investigator)
Toboroz
GCCC 2578 Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries
NCT07415681· 2. fázis· University of Maryland, Baltimore· Forrás
Contact: Caitlin Eggleston, BS
Toboroz
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
NCT06980480· 3. fázis· Takeda· Forrás
Contact: Mehmet Kocoglu (principal investigator)
Toboroz
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
NCT07213674· 3. fázis· Amgen· Forrás
Toboroz
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
NCT06769126· 2. fázis· SWOG Cancer Research Network· Forrás
Contact: Samuel Rosner (principal investigator)
Toboroz
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
NCT07061977· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Sarah A. Mcavoy (principal investigator)
Toboroz
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
NCT07001748· 2/3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Contact: Jeremy L. Davis (principal investigator)
Toboroz
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
NCT06484062· 1. fázis· National Cancer Institute (NCI)· Forrás
Contact: Vu H. Duong (principal investigator)
Fut, nem toboroz
Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer
NCT06732401· 3. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
NCT06745882· 2. fázis· H. Lee Moffitt Cancer Center and Research Institute· Forrás
Contact: Katherine Scilla, MD (principal investigator)
Toboroz
A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer
NCT06800339· 1. fázis· University of Maryland, Baltimore· Forrás
Contact: Caitlin Eggleston, MPH
Toboroz
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
NCT06401330· 3. fázis· Children's Oncology Group· Forrás
Contact: Teresa A. York (principal investigator)
Toboroz
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
NCT06287775· 1/2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Samuel Rosner (principal investigator)
Toboroz
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
NCT06589804· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Ranee Mehra (principal investigator)
Toboroz
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
NCT06661720· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Arif Hussain (principal investigator)
Toboroz
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT06418204· Wake Forest University Health Sciences· Forrás
Contact: Kathryn Kline (principal investigator)
Toboroz
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
NCT06475989· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Contact: Ranee Mehra (principal investigator)
Fut, nem toboroz
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT06500455· 3. fázis· NRG Oncology· Forrás
Toboroz
Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
NCT06546969· 1. fázis· University of Maryland, Baltimore· Forrás
Contact: Caitlin Eggleston, BS
Fut, nem toboroz
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
NCT06388564· 2. fázis· Incyte Corporation· Forrás
Toboroz
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
NCT06096844· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Katherine A. Scilla (principal investigator)
Toboroz
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
NCT05886049· 1. fázis· National Cancer Institute (NCI)· Forrás
Contact: Vu H. Duong (principal investigator)
Toboroz
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NCT06172296· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Teresa A. York (principal investigator)
Fut, nem toboroz
High-Risk Metachronous Oligometastatic Prostate Cancer Trial
NCT06212583· 2. fázis· University of Maryland, Baltimore· Forrás
Toboroz
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
NCT06088381· 2. fázis· University of Maryland, Baltimore· Forrás
Contact: Kelly Kitzmiller, BS
Fut, nem toboroz
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
NCT05564403· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT05987241· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Heather D. Mannuel (principal investigator)
Toboroz
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NCT05946213· 3. fázis· NRG Oncology· Forrás
Contact: Melissa A. Vyfhuis (principal investigator)
Fut, nem toboroz
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
NCT05554367· 2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel
NCT05751668· 2. fázis· Alliance for Clinical Trials in Oncology· Forrás
Toboroz
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· 3. fázis· NRG Oncology· Forrás
Contact: Katherine H. Tkaczuk (principal investigator)
Toboroz
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768· 3. fázis· SWOG Cancer Research Network· Forrás
Contact: Katherine H. Tkaczuk (principal investigator)
Toboroz
A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma
NCT05705531· Children's Oncology Group· Forrás
Contact: Teresa A. York (principal investigator)
Fut, nem toboroz
Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
NCT05600894· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Katherine H. Tkaczuk (principal investigator)
Toboroz
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05633615· 2. fázis· SWOG Cancer Research Network· Forrás
Contact: Jean A. Yared (principal investigator)
Fut, nem toboroz
Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia
NCT05303792· 2. fázis· Alliance for Clinical Trials in Oncology· Forrás
Toboroz
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
NCT05675410· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Teresa A. York (principal investigator)
Fut, nem toboroz
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
NCT05554328· 2. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT05564377· 2. fázis· National Cancer Institute (NCI)· Forrás
Contact: Ranee Mehra (principal investigator)
Fut, nem toboroz
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
NCT05063552· 2/3. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
NCT05327686· 2. fázis· NRG Oncology· Forrás
Toboroz
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
NCT05646316· 3. fázis· NRG Oncology· Forrás
Contact: Gautam G. Rao (principal investigator)
Showing 50 of 153.